BEIJING, Oct 31, 2007 (Xinhua via COMTEX) -- Recombinant human erythropoietin (EPO) injection product Epiao of Shenyang Sunshine Pharmaceutical Co., Ltd. (3Sbio, SSRX.NASDAQ) has seen brisk sales and now takes a market share of 37 percent in China.

Meanwhile, Amgen Corporation's Espo and Roche Corporation's Recormon have a share of 15 percent and 10 percent respectively in the Chinese market.

In part, this results from much lower price of Epiao, which, however, boasts 90 percent profit margin and makes up 70 percent of 3Sbio's sales revenue with annual growth rate of 30 percent.Since 1999, seven million units of Epiao have been marketed and currently Epiao is available in 800 large hospitals nationwide and the figure is expected to rise to over 920 by the end of 2007.

Plus, 3Sbio's recombinant human thrombopoietin injection product Tpiao, launched in 2006, posted sales revenue of 1.3 million U.S. dollars in the second accounting quarter, up 263 percent year-on-year.

3Sbio also plans to sell Epiao in European markets by 2011 and have six new candidate drugs for human papilloma virus vaccine.

The company has just released its second quarter financial statement reporting sales revenue of 5.7 million U.S. dollars, up 49. 2 percent year on year.